Jart Ate Franke Oosterhaven

Jart Ate Franke Oosterhaven

Auto-generated profile, based on publicly available information

Jart Ate Franke Oosterhaven

Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
JTJacob P. Thyssen
Jacob P. Thyssen
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
JAJose Hernan Alfonso
Jose Hernan Alfonso
KAKlaus E. Andersen
Klaus E. Andersen
IAIrena Angelova‐Fischer
Irena Angelova‐Fischer
TATove Agner
Tove Agner

24 May 2016 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
KPKlaziena Politiek
Klaziena Politiek
JOJart A. F. Oosterhaven
Jart A. F. Oosterhaven
KVKarin M. Vermeulen
Karin M. Vermeulen
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar

12 June 2019 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JOJart A.F. Oosterhaven
Jart A.F. Oosterhaven
AVAngelique Nadine Voorberg
Angelique Nadine Voorberg
GRGeertruida L.E. Romeijn
Geertruida L.E. Romeijn
MBMarjolein S. de Bruin‐Weller
Marjolein S. de Bruin‐Weller
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
Systemic treatment options for chronic hand eczema are limited. Dupilumab is used in atopic dermatitis (AD) but is not licensed for (isolated) hand eczema. In this observational prospective study we aimed to determine the response of hand eczema to dupilumab in patients with AD. Adult patients with hand eczema and AD received dupilumab s.c. at a 600 mg loading dose, followed by 300 mg every 2 weeks. Primary outcome was a minimum improvement of 75% on the Hand Eczema Severity Index after 16 weeks (HECSI‐75). Secondary outcomes were severity, measured using the Photographic guide; quality of life improvement as patient‐reported outcome, measured using the Dermatology Life Quality Index (DLQI); and AD severity, measured using the Eczema Area and Severity Index (EASI). Forty‐seven patients were included (32 males; mean age, 45 years). HECSI‐75 was achieved by 28 (60%). Mean HECSI score reduction was 49.2 points (range, 0–164; 95% within‐subject confidence interval, 46.4–52.0), which was already significantly decreased after 4 weeks (P < 0.001). DLQI score mean improvement was 8.8 points (standard deviation [SD], 6.0) or 70.0% decrease (SD, 26.4) (P < 0.001). Eighteen patients (38%) were classified as responders on the Photographic guide. There was no difference in response between chronic fissured and recurrent vesicular clinical subtypes. Similar percentages of patients achieving EASI‐75 and HECSI‐75 were seen after 16 weeks. In conclusion, this study shows a favorable response of hand eczema to dupilumab in patients with AD. This raises the question whether a response will also be seen in isolated hand eczema.

5 December 2018 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
JOJart A. F. Oosterhaven
Jart A. F. Oosterhaven
Wolfgang UterWolfgang Uter
Wolfgang Uter
WAWerner Aberer
Werner Aberer
José C. Armario-HitaJosé C. Armario-Hita
José C. Armario-Hita
BBBarbara K. Ballmer‐Weber
Barbara K. Ballmer‐Weber
OGon behalf of the ESSCA Working Group
on behalf of the ESSCA Working Group
Background Analyses of the European Surveillance System on Contact Allergies (ESSCA) database have focused primarily on prevalence of contact allergies to the European baseline series; overall and in subgroups of patients. However, affected body sites have hitherto not been addressed. Objective To determine prevalence of contact allergies for distinct body sites in patients with allergic contact dermatitis (ACD). Methods Analysis of data collected by ESSCA (www.essca‐dc.org) in consecutively patch tested patients, 2009‐2014, in 8 European countries. Cases were selected based on the presence of minimally one positive patch test to the baseline series, and a final diagnosis of ACD attributed to only one single body site. Results N=6,255 cases were analyzed. The head and hand were the most common single sites ACD was attributed to. Differences between countries were seen for several body sites. Nickel, fragrance mix I, cobalt and methylchloroisothiazolinone/methylisothiazolinone were the most frequent allergens reported for various body sites. Conclusion Distinct allergen patterns per body site were observed. However, contact allergies were probably not always relevant for the dermatitis that patients presented themselves with. Adding possibility to link positive patch test reactions to relevance, along with affected body sites should be a useful addition to data capturing systems.

1 July 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JOJ.A.F. Oosterhaven
J.A.F. Oosterhaven
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
Background The Hand Eczema Severity Index (HECSI) is used to measure severity of hand eczema. It is unclear what HECSI scores mean and what is the minimally important change (MIC). Furthermore, responsiveness has not been studied. Objectives To study responsiveness and interpretability of the HECSI. Methods Prospective study covering two time points; baseline and after 4‐12 weeks. Responsiveness was assessed using a criterion approach with a ≥ 1 step improvement on the ‘Photographic guide for severity of hand eczema' as anchor for important improvement. Interpretability of single scores was determined by defining severity bands based on agreement with the anchor. For change scores, smallest detectable change (SDC) was calculated in unchanged patients and MIC was obtained in changed patients using three methods: mean cut‐off, receiver operating curve (ROC) and 95%‐limit. Results N=294 patients participated (N=160 males, mean age 44·9). HECSI scores improved/deteriorated in parallel with the anchor. The area under the ROC curve was 0·86 (95% confidence interval: 0·81–0·91). The final severity band for single scores had a κ‐coefficient of agreement of 0·694: clear, 0; almost clear, 1‐16; moderate, 17‐37; severe, 38‐116; very severe, ≥117. The SDC in N=93 unchanged patients was 40·3 points. The obtained MIC values were all smaller than the SDC. Conclusions The HECSI has good responsiveness. This study gives meaning to HECSI scores, which can be applied to clinical decision making and the design of clinical trials. We recommend that an improvement of 41 points on the HECSI is regarded as minimally measurable true change.

12 July 2021 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
AVAngelique Nadine Voorberg
Angelique Nadine Voorberg
HNHanna Niehues
Hanna Niehues
JOJart A. F. Oosterhaven
Jart A. F. Oosterhaven
GRGeertruida L. E. Romeijn
Geertruida L. E. Romeijn
IVIvonne M. J. J. van Vlijmen‐Willems
Ivonne M. J. J. van Vlijmen‐Willems
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA‐sequencing. RNA‐sequencing was performed to identify differentially expressed genes in lesional vs. non‐lesional palmar epidermal skin from a group of patients with vesicular hand eczema compared to healthy controls. Comprehensive real‐time quantitative PCR analyses and immunohistochemistry were used for validation of candidate genes and protein profiles for vesicular hand eczema. Overall, a significant and high expression of genes/proteins involved in keratinocyte host defense and inflammation was found in lesional skin. Furthermore, we detected several molecules, both up or downregulated in lesional skin, which are involved in epidermal differentiation. Immune signalling genes were found to be upregulated in lesional skin, albeit with relatively low expression levels. Non‐lesional patient skin showed no significant differences compared to healthy control skin. Lesional vesicular hand eczema skin shows a distinct expression profile compared to non‐lesional skin and healthy control skin. Notably, the overall results indicate a large overlap between vesicular hand eczema and earlier reported atopic dermatitis lesional transcriptome profiles, which suggests that treatments for atopic dermatitis could also be effective in (vesicular) hand eczema.